Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to characterize the pharmacokinetic and pharmacodynamic
profile of dexmedetomidine administered as an intravenous loading dose followed by a
continuous intravenous infusion in pediatric subjects ages ≥2 through <17 years old.
Phase:
Phase 2
Details
Lead Sponsor:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer